Himadri Speciality Chemical Approves ₹368 Crore Capex for New Product Lines
Himadri Speciality Chemical approved ₹368 Crores in capex for new product lines. This includes ₹128 Crores for Anthraquinone and Carbazole capacity expansion, ₹70 Crores for India's first Carbon Nano Tube (CNT) facility, and ₹170 Crores for Super Speciality Carbon Black manufacturing. The company also announced its Unaudited Financial Results for the quarter ended June 30, 2026.
The substantial capex across multiple new product lines, including strategic entry into the Carbon Nano Tube market, is expected to significantly impact the company's future revenue, profitability, and market competitiveness.
The company is making significant capital investments in new, high-growth product lines and expanding existing capacities, indicating a positive outlook for future growth and market positioning.
Himadri Speciality Chemical Limited's Board of Directors, in a meeting held on July 15, 2026, approved significant capital expenditure (capex) plans totaling ₹368 Crores across multiple new product lines. The company will invest ₹128 Crores to expand the capacity for manufacturing Anthraquinone and Carbazole from 2600 MTPA to 5300 MTPA. This expansion will be implemented in two phases, with Phase 1 (2600 MTPA) expected by Q2FY27 and Phase 2 (2700 MTPA) by Q2FY28.
Furthermore, Himadri will invest ₹70 Crores to establish India's first manufacturing facility for Carbon Nano Tubes (CNT) in West Bengal, leveraging in-house developed technology. This facility will have an annual production capacity of 200 MT and is anticipated to be commissioned by Q4FY27. CNTs are crucial for industries like electric vehicles, electronics, composites, and energy storage.
In addition, the company approved a capex of ₹170 Crores for manufacturing Super Speciality Carbon Black (SSCB) with a capacity of 6,000 MTPA. This investment will be funded through internal accruals and is expected to be commissioned by Q4FY28. The SSCB production will enhance the company's value realization in niche applications.
The Board also took on record the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026. The meeting commenced at 11:30 a.m. (IST) and concluded at 3:25 p.m. (IST).
What to do with a filing like this
Himadri Speciality Chemical Limited filed this with the NSE as a statutory disclosure, categorised under capex. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Himadri Speciality Chemical Limited. Read the original for the full detail.